Literature DB >> 27446463

TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma.

Hasita Horlad1, Koji Ohnishi1, Chaoya Ma1, Yukio Fujiwara1, Daisuke Niino2, Koichi Ohshima2, Masahisa Jinushi3, Masao Matsuoka4, Motohiro Takeya1, Yoshihiro Komohara1.   

Abstract

Adult T-cell leukemia/lymphoma (ATLL), an aggressive type of malignant lymphoma, is highly resistant to chemotherapy. However, the detailed mechanisms of the chemoresistance of ATLL have never been elucidated. We previously demonstrated that direct cell-cell interaction between macrophages and lymphoma cells was significantly associated with lymphoma progression in patients with ATLL. The present study aimed to further analyze the effects of cell-cell interaction between macrophages and ATLL cells by means of cell culture studies and immunohistochemical analysis using human ATLL samples. It was found that direct co-culture with macrophages induced chemoresistance in the ATLL ATN-1 cell line, but not in other cell lines, including TL-Mor, ED and ATL-2S. It was also found that expression of the T cell Ig and mucin domain-containing molecule-3 (TIM-3) was induced in ATN-1 cells by their long-term co-culture with macrophages. TIM-3 gene transfection induced chemoresistance in the ATN-1 cells. Immunostaining of ATLL tissues showed TIM-3 expression in 25 out of 58 ATLL cases. Although TIM-3 expression was not associated with overall survival or T classification, it was associated with resistance to chemotherapy. TIM-3 expression is therefore considered to be a marker for predicting the efficacy of chemotherapy, and TIM-3-associated signals may be a therapeutic target for patients with ATLL.

Entities:  

Keywords:  TIM-3; adult T-cell leukemia/lymphoma; chemoresistance; cluster of differentiation 163; macrophage

Year:  2016        PMID: 27446463      PMCID: PMC4950894          DOI: 10.3892/ol.2016.4774

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  17 in total

1.  CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.

Authors:  Yu-Hwa Huang; Chen Zhu; Yasuyuki Kondo; Ana C Anderson; Amit Gandhi; Andrew Russell; Stephanie K Dougan; Britt-Sabina Petersen; Espen Melum; Thomas Pertel; Kiera L Clayton; Monika Raab; Qiang Chen; Nicole Beauchemin; Paul J Yazaki; Michal Pyzik; Mario A Ostrowski; Jonathan N Glickman; Christopher E Rudd; Hidde L Ploegh; Andre Franke; Gregory A Petsko; Vijay K Kuchroo; Richard S Blumberg
Journal:  Nature       Date:  2014-10-26       Impact factor: 49.962

2.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  Profiles of expression of activated cell antigens on peripheral blood and lymph node cells from different clinical stages of adult T-cell leukemia.

Authors:  K Shirono; T Hattori; H Hata; H Nishimura; K Takatsuki
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

4.  The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas.

Authors:  Yoshihiro Komohara; Tomoko Morita; Dorcas A Annan; Hasita Horlad; Koji Ohnishi; Sohsuke Yamada; Toshiyuki Nakayama; Shohei Kitada; Shinya Suzu; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Koichi Akashi; Motohiro Takeya; Masahisa Jinushi
Journal:  Cancer Immunol Res       Date:  2015-03-17       Impact factor: 11.151

5.  PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.

Authors:  Y Zheng; J Yang; J Qian; P Qiu; S Hanabuchi; Y Lu; Z Wang; Z Liu; H Li; J He; P Lin; D Weber; R E Davis; L Kwak; Z Cai; Q Yi
Journal:  Leukemia       Date:  2012-09-21       Impact factor: 11.528

Review 6.  Role of tumor-associated macrophages in hematological malignancies.

Authors:  Yoshihiro Komohara; Daisuke Niino; Koji Ohnishi; Koichi Ohshima; Motohiro Takeya
Journal:  Pathol Int       Date:  2015-02-23       Impact factor: 2.534

Review 7.  Pathological features of diseases associated with human T-cell leukemia virus type I.

Authors:  Koichi Ohshima
Journal:  Cancer Sci       Date:  2007-03-27       Impact factor: 6.716

8.  Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1.

Authors:  Shigeki Chiba; Muhammad Baghdadi; Hisaya Akiba; Hironori Yoshiyama; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Yoichiro Fujioka; Yusuke Ohba; Jacob V Gorman; John D Colgan; Mitsuomi Hirashima; Toshimitsu Uede; Akinori Takaoka; Hideo Yagita; Masahisa Jinushi
Journal:  Nat Immunol       Date:  2012-07-29       Impact factor: 25.606

9.  Tumor immunity times out: TIM-3 and HMGB1.

Authors:  Daolin Tang; Michael T Lotze
Journal:  Nat Immunol       Date:  2012-09       Impact factor: 25.606

10.  Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC.

Authors:  Xuewei Zhuang; Xiaoning Zhang; Xiyan Xia; Cuijuan Zhang; Xiaohong Liang; Lifen Gao; Xin Zhang; Chunhong Ma
Journal:  Am J Clin Pathol       Date:  2012-06       Impact factor: 2.493

View more
  6 in total

Review 1.  Can we use epigenetics to prime chemoresistant lymphomas?

Authors:  Jennifer E Amengual
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

2.  Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells.

Authors:  Yizi Cong; Yuxin Cui; Shiguang Zhu; Jianqiao Cao; Haidong Zou; Tracey A Martin; Guangdong Qiao; Wenguo Jiang; Zhigang Yu
Journal:  Chin J Cancer Res       Date:  2020-10-31       Impact factor: 5.087

3.  Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.

Authors:  Yang Zhao; Hui Xu; Mingzhi Zhang; Ling Li
Journal:  Front Genet       Date:  2022-05-04       Impact factor: 4.772

4.  Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression.

Authors:  Muming Yu; Bin Lu; Yancun Liu; Ying Me; Lijun Wang; Peng Zhang
Journal:  Mol Med Rep       Date:  2016-12-22       Impact factor: 2.952

Review 5.  Tumor microenvironment of adult T-cell leukemia/lymphoma.

Authors:  Mai Takeuchi; Hiroaki Miyoshi; Koichi Ohshima
Journal:  J Clin Exp Hematop       Date:  2021

Review 6.  Immune-Checkpoint Blockade Therapy in Lymphoma.

Authors:  Ayumi Kuzume; SungGi Chi; Nobuhiko Yamauchi; Yosuke Minami
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.